摘要
目的:探讨血小板N糖β1,6-GlcNAc分支缺陷对骨髓来源巨噬细胞(BMDMs)极化的影响。方法:通过苦马豆素灌胃动物模型获取N糖β1,6-GlcNAc分支缺陷血小板,流式细胞术检测血小板表面N糖β1,6-GlcNAc分支表达水平。将正常血小板和N糖支链缺陷血小板分别与BMDMs共同培养,采用流式细胞术、RT-PCR、ELISA等方法检测BMDMs的表型特征。结果:苦马豆素处理后的小鼠血小板N糖β1,6-GlcNAc表达较正常血小板明显减低(P<0.05)。与BMDMs共培养后,和正常血小板相比,N糖β1,6-GlcNAc分支缺陷血小板能够诱导巨噬细胞表达更多的诱导型一氧化氮合酶(iNOS)、CD16/32以及肿瘤坏死因子-ɑ(TNF-α),并降低CD206、Dectin-1、精氨酸酶-1(Arg-1)、白介素-10(IL-10)的表达。结论:N糖β1,6-GlcNAc分支缺陷血小板可在体外诱导BMDMs发生M1型极化,这可能是原发免疫性血小板减少症中免疫紊乱的发生机制之一。
Objective:To investigate the effects of defective N-glycanβ1,6-GlcNAc branch on platelets during the differentiation of bone marrow-derived macrophages(BMDMs)in vivo.Methods:Platelets with defective N-glycanβ1,6-GlcNAc was obtained by swainsonine gavage,which was confirmed by flow cytometry.BMDMs were co-cultured with normal or abnormal platelets.Then the phenotype of BMDMs was determined by flow cytometry,RT-PCR and ELISA.Results:Platelets in swainsoine-treated mice expressed lower N-glycanβ1,6-GlcNAc branch compared with that in normal mice.After co-cultured with BMDMs,abnormal platelets produced increased inducible nitric oxide synthase(iNOS),CD16/CD32 and tumor necrosis factor(TNF-ɑ),while the expression of CD206,Dectin-1,Arg-1 and IL-10 were down-regulated,compared with normal control.Conclusion:N-glycanβ1,6-GlcNAc-defective platelets could induce the differentiation of BMDMs into proinflammatory M1 phenotype in vitro,which would be probably involved in pathogenesis of primary immune thrombocytopenia.
作者
蔡惠丽
邹雅倩
周蜜
王勃霏
易虹
王树林
郭静明
Cai Huili;Zou Yaqian;Zhou Mi;Wang Bofei;Yi Hong;Wang Shulin;Guo Jingming(Department of Hematology,Yichang Central People's Hospital,The First College of Clinical Medical Science,China Three Gorges University&Institute of Hematology,China Three Gorges University,Yichang 443003,China;Department of Spinal Surgery,Yichang Central People's Hospital,The First College of Clinical Medical Science,China Three Gorges University,Yichang 443003,China)
出处
《巴楚医学》
2020年第4期6-10,共5页
Bachu Medical Journal
基金
湖北省自然科学基金青年项目(No:2017CFB334)
湖北省教育厅科学研究项目(No:B2017018)
湖北省卫生和计划生育委员会科研项目(No:WJ2017M222)。